SARCLISA
Sep 24, 2024
Unleashing the Potential: CD38 Directed Therapies Revolutionize Multiple Myeloma Treatment
The landscape of multiple myeloma therapies has been revolutionized by the introduction of cutting-edge monoclonal antibodies (mAbs) targeting CD38. Among the standout advancements are DARZALEX (daratumumab) and SARCLISA (isatuximab-irfc), which have emerged as game-changers in the treatment of multiple myeloma. Th...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
